LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
LL-37 is being researched for inflammation applications. Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bac. Common dosages for this use range from 100-500 mcg (topical/local application) topical or local application as needed.
Can LL-37 Help With Inflammation?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is being researched for inflammation applications based on its mechanism as a Antimicrobial peptide, host defense peptide.
Kills pathogens through multiple mechanisms: converts from random coil to α-helix structure, burrows into bacterial membranes causing permeabilization (carpet model), generates oxidative stress in bacterial cells, and disrupts biofilms and viral envelopes. Also immunomodulatory — activates chemokine receptors and enhances inflammatory response. Effective against 38+ bacteria, 16 fungi, and 16 viruses.
What Does the Research Show for LL-37 and Inflammation?
Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
The relevance to inflammation specifically comes from LL-37's effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What Protocol Is Used for Inflammation?
For inflammation applications, the standard LL-37 protocol is 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal for acute use as needed.
Some researchers adjust dosing based on the specific inflammation application — see our LL-37 dosage guide for full protocol details.
Can Stacking Improve Inflammation Results?
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair.
What Side Effects Apply to Inflammation Use?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Side effects are generally consistent regardless of the specific application. See our LL-37 side effects guide for details.
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Bottom Line: LL-37 for Inflammation
LL-37 shows preliminary research potential for inflammation. Standard protocols (100-500 mcg (topical/local application), topical or local application as needed, acute use as needed) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.